HEMLIBRA (EMICIZUMAB-KXWH)

105 mg/0.7 mL subcutaneous solution

• Dosage information is not available

150 mg/mL subcutaneous solution

• Dosage information is not available

30 mg/mL subcutaneous solution

• Dosage information is not available

60 mg/0.4 mL subcutaneous solution

• Dosage information is not available

Bleeding prevention in hereditary factor VIII deficiency

• Inject 3 mg/kg by subcutaneous route once weekly for 4 weeks in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 1.5 mg/kg by subcutaneous route once weekly in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 3 mg/kg by subcutaneous route once weekly for 4 weeks, followed by 1.5 mg/kg once weekly in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 3 mg/kg by subcutaneous route every 2 weeks in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 6 mg/kg by subcutaneous route every 4 weeks in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 3 mg/kg by subcutaneous route once weekly for 4 weeks, followed by 3 mg/kg every 2 weeks in the abdomen, thighs, or outer area of upper arm rotating injection sites

• Inject 3 mg/kg by subcutaneous route once weekly for 4 weeks, followed by 6 mg/kg every 4 weeks in the abdomen, thighs, or outer area of upper arm rotating injection sites